英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字,中文词皆可:


请选择你想看的字典辞典:
单词字典翻译
Morfey查看 Morfey 在百度字典中的解释百度英翻中〔查看〕
Morfey查看 Morfey 在Google字典中的解释Google英翻中〔查看〕
Morfey查看 Morfey 在Yahoo字典中的解释Yahoo英翻中〔查看〕





安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Alector Therapeutics for Neurodegenerative Disease
    Alector is a biopharmaceutical company that develops therapies for the treatment of neurodegeneration diseases
  • Pipeline for Neurodegenerative Diseases - Alector
    Our pipeline provides an overview of our late-stage clinical development programs for neurodegenerative diseases
  • About Us - Alector
    Alector is on a mission to erase neurodegenerative diseases We exist to restore the experience of life for patients, caregivers, and families
  • Investors | Alector
    The Investor Relations website contains information about Alector's business for stockholders, potential investors, and financial analysts
  • Press Releases - Alector
    The Investor Relations website contains information about Alector's business for stockholders, potential investors, and financial analysts
  • Culture and Careers - Alector
    Alector offers a 401 (k) match, flexible spending accounts, an employee stock purchase plan, company-paid life insurance, financial planning services, and company-paid short- and long-term disability insurance Whether you’re looking to drive or take public transit, commuting to Alector’s office is a breeze
  • Our Executive Leadership Board of Directors - Alector
    Alector is led by a seasoned team of inventors, scientists, and big thinkers We combine our deep expertise to deliver life-transforming medicines
  • Our History Overview - Alector
    Alector was founded in 2013 Read through our history and highlights along the way from our journey in developing neurodegeneration medication
  • AL001 – Frontotemporal dementia with a progranulin mutation - Alector
    AL001 modulates progranulin (PGRN), a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders We are initially developing AL001 for frontotemporal dementia (FTD) with progranulin mutation (FTD- GRN) The global INFRONT-3 Phase 3 clinical trial is currently enrolling both at-risk and symptomatic participants with FTD- GRN AL001 is being
  • Patient Education - Alector
    Alector’s patients information can be a resource for patients, caregivers and family members Read more about how Alector may help you





中文字典-英文字典  2005-2009